The role of depot neuroleptics in the treatment of schizophrenic patients.
Because of the potential importance of prolonged action neuroleptics for the delivery of care to schizophrenic patients, and because of the availability of new, extensive data from clinical trials on the utility of these drugs, a workshop conference was convened by the United States National Institute of Mental Health in collaboration with the Institute of Clinical Psychiatry of the University of Pisa to assess the role of depot neuroleptics in the treatment of schizophrenic patients. This paper summarizes its conclusions.
D000208:Acute Disease; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations